257 related articles for article (PubMed ID: 31656047)
21. CAR-T bridging to allo-HSCT as a treatment strategy for relapsed adult acute B-lymphoblastic leukemia: a case report.
Wen S; Niu Z; Xing L; Wang Y; Li H; Kuang N; Luo J; Zhang X; Wang F
BMC Cancer; 2018 Nov; 18(1):1143. PubMed ID: 30458755
[TBL] [Abstract][Full Text] [Related]
22. An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells.
Zhang Y; Zhang W; Dai H; Wang Y; Shi F; Wang C; Guo Y; Liu Y; Chen M; Feng K; Zhang Y; Liu C; Yang Q; Li S; Han W
Sci China Life Sci; 2016 Apr; 59(4):379-85. PubMed ID: 27009300
[TBL] [Abstract][Full Text] [Related]
23. Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.
Aldoss I; Bargou RC; Nagorsen D; Friberg GR; Baeuerle PA; Forman SJ
Leukemia; 2017 Apr; 31(4):777-787. PubMed ID: 28028314
[TBL] [Abstract][Full Text] [Related]
24. Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy.
Shadman M; Gauthier J; Hay KA; Voutsinas JM; Milano F; Li A; Hirayama AV; Sorror ML; Cherian S; Chen X; Cassaday RD; Till BG; Gopal AK; Sandmaier BM; Maloney DG; Turtle CJ
Blood Adv; 2019 Oct; 3(20):3062-3069. PubMed ID: 31648329
[TBL] [Abstract][Full Text] [Related]
25. Emerging role of immunotherapy in precursor B-cell acute lymphoblastic leukemia.
Valecha GK; Ibrahim U; Ghanem S; Asti D; Atallah JP; Terjanian T
Expert Rev Hematol; 2017 Sep; 10(9):783-799. PubMed ID: 28666090
[TBL] [Abstract][Full Text] [Related]
26. Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia.
Cai B; Guo M; Wang Y; Zhang Y; Yang J; Guo Y; Dai H; Yu C; Sun Q; Qiao J; Hu K; Zuo H; Dong Z; Zhang Z; Feng M; Li B; Sun Y; Liu T; Liu Z; Wang Y; Huang Y; Yao B; Han W; Ai H
J Hematol Oncol; 2016 Nov; 9(1):131. PubMed ID: 27887660
[TBL] [Abstract][Full Text] [Related]
27. Posttransplant chimeric antigen receptor therapy.
Smith M; Zakrzewski J; James S; Sadelain M
Blood; 2018 Mar; 131(10):1045-1052. PubMed ID: 29358181
[TBL] [Abstract][Full Text] [Related]
28. CAR19/22 T cell cocktail therapy for B-ALL relapsed after allogeneic hematopoietic stem cell transplantation.
Yan N; Wang N; Wang G; Huang L; Li C; Wang D; Wang J; Huang L; Meng F; Wei J; Chen L; Mao X; Zhou J; Zhang Y; Cao Y
Cytotherapy; 2022 Aug; 24(8):841-849. PubMed ID: 35256277
[TBL] [Abstract][Full Text] [Related]
29. Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia.
Mueller KT; Waldron E; Grupp SA; Levine JE; Laetsch TW; Pulsipher MA; Boyer MW; August KJ; Hamilton J; Awasthi R; Stein AM; Sickert D; Chakraborty A; Levine BL; June CH; Tomassian L; Shah SS; Leung M; Taran T; Wood PA; Maude SL
Clin Cancer Res; 2018 Dec; 24(24):6175-6184. PubMed ID: 30190371
[TBL] [Abstract][Full Text] [Related]
30. Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant.
Zhang C; Wang XQ; Zhang RL; Liu F; Wang Y; Yan ZL; Song YP; Yang T; Li P; Wang Z; Ma YY; Gao L; Liu Y; Gao L; Kong PY; Liu J; Tan X; Zhong JF; Chen YQ; Liang AB; Ren JH; Li ZY; Cao J; Gao QL; Zhou J; Gao Y; Zhang D; Fan FY; Han MZ; Gale RP; Zhang X
Leukemia; 2021 Jun; 35(6):1563-1570. PubMed ID: 33077866
[TBL] [Abstract][Full Text] [Related]
31. Chimeric Antigen Receptor Therapy in Acute Lymphoblastic Leukemia Clinical Practice.
Luskin MR; DeAngelo DJ
Curr Hematol Malig Rep; 2017 Aug; 12(4):370-379. PubMed ID: 28656487
[TBL] [Abstract][Full Text] [Related]
32. Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia.
Ceppi F; Gardner RA
Cancer J; 2019; 25(3):191-198. PubMed ID: 31135526
[TBL] [Abstract][Full Text] [Related]
33. Advances in the development of chimeric antigen receptor-T-cell therapy in B-cell acute lymphoblastic leukemia.
Zhang X; Li JJ; Lu PH
Chin Med J (Engl); 2020 Feb; 133(4):474-482. PubMed ID: 31977556
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of Anti-CD19 chimeric antigen receptor T-Cell therapy in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia. A societal view.
Thielen FW; van Dongen-Leunis A; Arons AMM; Ladestein JR; Hoogerbrugge PM; Uyl-de Groot CA
Eur J Haematol; 2020 Aug; 105(2):203-215. PubMed ID: 32289184
[TBL] [Abstract][Full Text] [Related]
35. PiggyBac-Engineered T Cells Expressing CD19-Specific CARs that Lack IgG1 Fc Spacers Have Potent Activity against B-ALL Xenografts.
Bishop DC; Xu N; Tse B; O'Brien TA; Gottlieb DJ; Dolnikov A; Micklethwaite KP
Mol Ther; 2018 Aug; 26(8):1883-1895. PubMed ID: 29861327
[TBL] [Abstract][Full Text] [Related]
36. A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia.
Martino M; Alati C; Canale FA; Musuraca G; Martinelli G; Cerchione C
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670075
[TBL] [Abstract][Full Text] [Related]
37. Immunophenotypic changes in leukemic blasts in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia after treatment with CD19-directed chimeric antigen receptor (CAR)- expressing T cells.
Mikhailova E; Illarionova O; Shelikhova L; Zerkalenkova E; Molostova O; Olshanskaya Y; Novichkova G; Maschan A; Maschan M; Popov A
Haematologica; 2022 Apr; 107(4):970-974. PubMed ID: 34911282
[No Abstract] [Full Text] [Related]
38. Long-term outcomes of Sleeping Beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas.
Srour SA; Singh H; McCarty J; de Groot E; Huls H; Rondon G; Qazilbash M; Ciurea S; Bardelli G; Buck J; Alousi A; Nieto Y; Rezvani K; Marin D; Popat U; Hosing C; Shpall EJ; Wierda WG; Kantarjian H; Champlin RE; Cooper LJ; Kebriaei P
Blood; 2020 Mar; 135(11):862-865. PubMed ID: 31961918
[No Abstract] [Full Text] [Related]
39. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy.
Gardner R; Wu D; Cherian S; Fang M; Hanafi LA; Finney O; Smithers H; Jensen MC; Riddell SR; Maloney DG; Turtle CJ
Blood; 2016 May; 127(20):2406-10. PubMed ID: 26907630
[TBL] [Abstract][Full Text] [Related]
40. Long-term remission in a patient with relapsed Richter's transformation treated with CD19-directed chimeric antigen-receptor T-cells after allogeneic stem cell transplantation.
Kutsch N; Gödel P; Voltin CA; Hallek M; Scheid C; Borchmann P; Holtick U
Eur J Haematol; 2024 Jun; 112(6):984-987. PubMed ID: 38316549
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
